Skip to main content
. Author manuscript; available in PMC: 2009 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2008 Apr;7(4):905–914. doi: 10.1158/1535-7163.MCT-07-0515

Figure 3.

Figure 3

Independent effects of UBP43 on RA- and UBE1L-mediated repression of PML/RARα and its domains. BEAS-2B cells were independently transfected with (A) PML/RARα, (B) PML, or (C) RARα domain containing expression vectors. Indicated groups were either cotransfected with UBE1L or treated for 24 h with vehicle (DMSO) or RA (1 μmol/L). Cells were also cotransfected with or without a UBP43 expression vector as indicated. Immunoblot analyses revealed that UBP43 preferentially opposes UBE1L- but not RA-mediated repression of the indicated PML/RARα species. Bottom, quantification of each of these signals.